Healthcare
Live Price
Offline$3.23
+3.86% today
1Y Change
-31.88%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Recursion Pharmaceuticals, Inc. (RXRX) is a Healthcare stock with a market cap of $1.57B and listed on NASDAQ. The stock last traded around $3.23 and down 31.9% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +26.9%, EPS growth of +14.8%, a dividend yield of 0.0%. What stands out right now is revenue +26.9%, EPS +14.8%, free cash flow -1.5% with operating margin -869.3% and ROIC -48.1%. Valuation already assumes a fairly strong business story at price/sales 21.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RXRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RXRX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RXRX Max Drawdown
-58.17%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RXRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$10.0M
-74.8% YoY
FY Net Income
-$186.5M
+22.1% YoY
Free Cash Flow
-$198.4M
-64.1% YoY
Revenue Growth
+26.9%
EPS Growth
+14.8%
Gross Margin
-32.1%
Net Margin
-864.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 75M | 59M | 44M | 40M | 10M |
| Gross Profit | -46M | 14M | 1M | -9M | 10M |
| Operating Income | -648M | -479M | -350M | -246M | -183M |
| EBITDA | -559M | -427M | -308M | -228M | -175M |
| Net Income | -645M | -464M | -328M | -239M | -186M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 743M | 594M | 392M | 550M | 285M |
| Total Assets | 1.5B | 1.4B | 654M | 701M | 610M |
| Total Liabilities | 343M | 414M | 190M | 215M | 67M |
| Shareholder Equity | 1.1B | 1.0B | 463M | 486M | 543M |
| Total Debt | 78M | 108M | 51M | 51M | 11M |
| Net Debt | -665M | -486M | -341M | -499M | -274M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
159M
-89.9% YoY
Capital Expenditures
40M
-6.5% YoY
Free Cash Flow
198M
-64.1% YoY
Key ratios
Gross Margin
-32.1%
Operating Margin
-869.3%
Net Margin
-864.7%
ROE
-64.0%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.